Anil Kumar, Retrotope president
An ultra-rare disease drug missed on function but hit on survival and mortality. Is it enough for the FDA?
A California company developing a drug for an ultra-rare, universally fatal neurological disease manifesting in infancy reported Wednesday that its therapy missed the primary endpoint …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
